69. ESMO 2023 - Metastatic Breast Cancer

Updates in metastatic triple-negative breast cancer at ESMO 2023Подробнее

How to use endocrine therapy in premenopausal women with ER+ metastatic breast cancerПодробнее

#ESMO21 Expert Video Report on HER2-positive metastatic breast cancerПодробнее

ESMO 2023: Key messages for breast cancer treatmentПодробнее

Adjuvant treatment for high risk HR+ breast cancer | ESMO 2023 Breast Cancer HighlightsПодробнее

ESMO 2023 Breast Cancer Highlights – Keynote 756, TROPION-Breast01, Keynote 52 | Onc BrothersПодробнее

How to sequence ADCs in breast cancer? | ESMO 2023 Breast Cancer HighlightsПодробнее

Rodrigo Sánchez-Bayona My #ESMOBreast23 highlight (day 1)Подробнее

Advancements in metastatic ER+ breast cancer at ESMO Breast 2024Подробнее

ESO-ESMO-ABC guidelines in metastatic breast cancerПодробнее

Emergence of antibody-drug conjugates in metastatic breast cancer: 2022 ESMO FloridaПодробнее

Breast cancer at ESMO 2023: ADCs and MONARCH 3Подробнее

Expert report on tackling resistance to CDK4/6 inhibitors in ER+/HER2-metastatic breast cancerПодробнее

ASCO 2023 Expert Report in HR positive, HER2 negative breast cancer by Catherine Harper-WynneПодробнее

GU Summary for ESMO 2023 | Dr. Rana McKay | Oncology Brothers #oncologyПодробнее

HER2-low breast cancer: the ESMO Expert Consensus StatementsПодробнее

New Results on Treatment of Metastatic Breast Cancer - European Cancer Congress (ESMO) 2023Подробнее

NEJM at ESMO — Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast CancerПодробнее

2023 What Changes Monday Morning? | ESMO Breast Cancer WebinarПодробнее